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Aortic Atheromas and Historical Justice
We read with great interest the article by Dressler et al. (1)
dealing with the efficacy of anticoagulation and influence of
plaque morphology on recurrent stroke. Their findings are
in keeping with those of a recent report from our laboratory
stressing the importance of disrupted aortic plaques as a
major risk factor for systemic embolism in the elderly (2).
Moreover, the suggestion that anticoagulation should be the
treatment of choice in patients with mobile aortic athero-
mas—even in those with small mobile components—
represents a valuable contribution in the yet controversial
therapeutic approach to this challenging clinical problem.
We would like to bring to the authors’ attention two
points. First is an oversight in the Results section. When
describing the follow-up events of patients with atheroma,
readers are referred to Table 2, but this table deals only with
plaque dimensions (repeating data given in the text). The
next paragraph analyzes the influence of anticoagulation on
recurrent stroke in the three morphologic groups, and
readers are referred to Table 3, which actually deals with
follow-up events. We believe that these errors are probably
derived from a misprint that omitted the “true” Table 3,
data that would be interesting to see.
Second, it is stated at the beginning of the article that
“nearly 40 years have passed since the aorta was first
recognized as a source for systemic emboli,” quoting the
description by Winter of cerebral infarction caused by
atheromatous emboli (3). In fact, the entity had already
been described in the last century; experimental emboliza-
tion from aortic source was reported as early as in 1862 (4).
In addition, autopsy evidence of arterial occlusions by emboli
from eroded aortic atheromatous plaques was published in
1945 (5), twelve years before Winter’s communication. Today,
when the role of aortic atheromas in systemic emboli seems to
be obvious, historical justice requires that the pioneering works
of Panum and Flory should not be forgotten.
Enrique Z. Fisman, MD
Alexander Tenenbaum, MD, PhD
Cardiac Rehabilitation Institute
Chaim Sheba Medical Center
Tel-Aviv University
Tel-Aviv, Israel
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The Malpractice Crisis and
the “Expert” Witness:
The Problem and a Proposed Solution
Malpractice litigation in the U.S. has reached crisis. Premi-
ums for malpractice insurance are often astronomical, in
some cases forcing physicians out of practice, and the fear of
legal attack, often unjustified and even frivoulous, dogs
every practitioner. The entire structure of malpractice liti-
gation rests on expert testimony. Without expert testimony,
no malpractice action could ever succeed, and it comes as a
shock to realize that the malpractice crisis in the U.S. is only
made possible by certain physicians offering expert testi-
mony for large fees on either side of any case. These
individuals actually advertise their wares in legal journals,
sometimes as corporations of professional witnesses.
Knowledgeable attorneys are completely cynical about these
individuals: They know that they can hire a physician to
testify to “anything, absolutely anything”—to quote one of
the leading trial lawyers in the U.S.
There are remedies. Under British law, a witness, expert
or not, cannot be paid for testimony. Any evidence of
payment excludes the witness. (Under British law there are
no contingent fees for counsel, another wholesome provi-
sion.) My personal response is simple but effective and may
serve as a paradigm for the country. I offer my services, free
of charge, for any case within my competence. I review the
file, advise counsel and appear to testify if necessary. I am
careful to explain that I do this as a public service, with no
question of remuneration, as an obligation I feel I owe my
profession and the public. If there is evidence of gross
incompetence, I advise counsel to settle. If I see perjured
expert testimony, I am glad to take the stand to describe it
as such. This is well and good as far as it goes, but after some
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years of experience, I have learned two alarming facts. First,
conversations with jurors after a trial reveal that jurors accept
the testimony of professional witness without prejudice. The
fact that a physician makes a living testifying against other
physicians does not seem to disturb them. Second, the tech-
nicalities involved in many malpractice cases are light-years
outside the competence of the average jury: Lawyers and
professional witnesses are quick to take advantage of this fact.
Major legal reforms are urgent. The following steps are
logical and feasible: 1) The jury system should be excluded
in a professional liability hearing; 2) A judge should reach a
final verdict on the basis of expert testimony provided by
members of a panel of disinterested, objective, acknowledged
experts. A permanent panel of such experts should be main-
tained and the expert testimony should be provided gratis: At
most, the witness should be reimbursed for out-of-pocket
expenses. (The various specialty colleges could easily compile
such lists.); 3) The British system of loser-pays-all should be
adopted; and 4) The British system of absolutely excluding
testimony by a paid witness should be adopted.
Obviously, this solution will take time. In the interim, a
practicable palliative measure lies ready at hand. I urge my
colleagues to offer their services as I do, as an unpaid, impartial
expert, ready to review any case in my respective disciplines: If
they explain to the legal fraternity that they do this pro bono,
this simple measure will have a substantial influence.
As a first step, the several specialty colleges could compile
lists of volunteer impartial expert witnesses and provide
defendants with names in any given geographic locale when
a suit is filed. I find that a number of colleagues around the
country are doing exactly what I do, and we agree that the
work is not particularly onerous because it is possible to
review any hospital record and reach conclusions in about 30
minutes.
The malpractice crisis can be overcome by simple, fair-
minded measures. It is time for the several organized
specialty groups and organized medicine in general to take
appropriate steps.
Brendan P. Phibbs, MD
Padre Kino Hospital
Heart Station
2800 E. Ajo Way
Tucson, Arizona 85713
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The Influence of Age and
Gender On Heart Rate Variability (HRV)
The recent article of Umetani et al. (1) on the relation of
time domain heart rate variability (HRV) and heart rate
(HR) to age and gender presented much important infor-
mation. Nevertheless, there are serious inconsistencies in
their methodology and not all conclusions are substantiated
by their results. Although the authors acknowledge that it is
recognized that a (logarithmic) tranformation is necessary to
achieve a normal distribution of certain HRV indices, it is
not clear which tranformation, if any, was performed before
tests that require normally distributed variables, such as
Student t test or ANOVA, were used. A normal distribu-
tion, tested by e.g., the one sample Kolmogorov-Smirnov
test, can be obtained by a natural logarithmic transformation
for rMSSD and by calculating the square root for pNN50
(2). Furthermore, all age groups above 60 are substantially
underrepresented (e.g., only six men in the age category
80–99). Therefore, statements as “HRV . . . exhibits an
accelerated decline the . . . ninth and tenth decades” should
be interpreted with caution. Statistical analysis on a two-
decade basis to ensure an “adequate number” of subjects in
each group is an artifice that is not warranted because first,
a rapid evolution in autonomic modulation between the ages
of 10 and 30 can be expected, and second, the disappearance
of the gender difference is situated in the decade beyond age
40 (2), and not, as stated by the authors, between 50 and 69.
The authors report that the correlations of SD and
SDANN with age were lower than those of SDNN index,
rMSSD and pNN50. However, they fail to mention that
this can be attributed solely to an absence of any correlation
for SD and SDANN with age in female subjects. In Figure
3, correlation coefficients of r 5 –0.24 and –0.20 are
presented for women, which can be disregarded, because in
biomedical sciences, they indicate only little or no relation-
ship (3).
We disagree with the statement that the gender differ-
ences they observed could reflect lower levels of parasym-
pathetic activity in “young” female subjects and that this
view is supported by a higher HR in female subjects. This
may be true for teenagers, but not for adults (2). In their
two-decade age group 30–49 HR is still significantly higher
in women, and no significant difference in vagal indices is
detected. The suggestion that this may be related to a higher
level of sympathetic activity is not substantiated by the
results. SDNN index has not been accepted as a substitute
for heart rate spectral analysis (HRSA) low-frequency
power (4), the only available parameter that reflects pre-
dominantly sympathetic modulation (5) in physiological
conditions. HRSA was not performed in this study. The
higher HR in female patients can also be related to their
lower stroke volume. Furthermore, the reported gender
differences may derive from different central autonomic and
neurohumoral mechanisms in male and female patients
rather than solely from differences in autonomic outflow or
modulation.
No correction was made in the statistical analysis for
mean HR, a major determinant of HRV (6), and day/night
changes, that markedly affect autonomic modulation, were
not taken into account.
The reported results (1) complete previous reports on the
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